Alyftrek 10-50-125 MG tablet 14S
Ended Awarded
- Contract number
- SPE2DR26FJUS9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,991
Award facts
- Contract value 100% obligated
- $41,990.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at approximately $42K to DMS Pharmaceutical Group Inc. for ALYFTREK 10-50-125 mg tablets (14-count units) on November 18, 2025, with an ultimate completion date of November 19, 2025. This award utilizes a firm fixed-price delivery order structure with no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the sole prime contractor with no identified subcontractors on this engagement.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to provide pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded November 13, 2025, carries a $500M ceiling value through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning the company as a critical pharmaceutical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FJUS9?
SPE2DR26FJUS9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FJUS9 worth?
The government has obligated $41,991 on SPE2DR26FJUS9.
Is contract SPE2DR26FJUS9 an order under another contract?
Yes. SPE2DR26FJUS9 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUS9 competed?
The extent of competition for SPE2DR26FJUS9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award